Related references
Note: Only part of the references are listed.Update on the laboratory investigation of dyslipidemias
I. Ramasamy
CLINICA CHIMICA ACTA (2018)
Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM
Michel R. Langlois et al.
CLINICAL CHEMISTRY (2018)
Advances in lipid-lowering therapy through gene-silencing technologies
Borge G. Nordestgaard et al.
NATURE REVIEWS CARDIOLOGY (2018)
Fasting Versus Nonfasting and Low-Density Lipoprotein Cholesterol Accuracy
Vasanth Sathiyakumar et al.
CIRCULATION (2018)
Remnant Cholesterol and Myocardial Infarction in Normal Weight, Overweight, and Obese Individuals from the Copenhagen General Population Study
Anette Varbo et al.
CLINICAL CHEMISTRY (2018)
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
Brian A. Ference et al.
EUROPEAN HEART JOURNAL (2017)
A Test in Context: Lipoprotein(a) Diagnosis, Prognosis, Controversies, and Emerging Therapies
Sotirios Tsimikas
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Very-Low-Density Lipoprotein- Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III
Raimund Pechlaner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
A Test in Context: Lipid Profile, Fasting Versus Nonfasting
Borge G. Nordestgaard
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Genetics of coronary artery disease: discovery, biology and clinical translation
Amit V. Khera et al.
NATURE REVIEWS GENETICS (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Women's Health Study
Julian C. van Capelleveen et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2017)
Remnant lipoproteins
Anette Varbo et al.
CURRENT OPINION IN LIPIDOLOGY (2017)
Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)
Amit V. Khera et al.
CIRCULATION (2017)
Discordance between Circulating Atherogenic Cholesterol Mass and Lipoprotein Particle Concentration in Relation to Future Coronary Events in Women
Patrick R. Lawler et al.
CLINICAL CHEMISTRY (2017)
Automated Multiplex LC-MS/MS Assay for Quantifying Serum Apolipoproteins A-I, B, C-I, C-II, C-III, and E with Qualitative Apolipoprotein E Phenotyping
Irene van den Broek et al.
CLINICAL CHEMISTRY (2016)
The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis
Michael J. Lipinski et al.
EUROPEAN HEART JOURNAL (2016)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)
Alberico L. Catapano et al.
ATHEROSCLEROSIS (2016)
2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult
Todd J. Anderson et al.
CANADIAN JOURNAL OF CARDIOLOGY (2016)
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
Robert S. Rosenson et al.
CARDIOVASCULAR DRUGS AND THERAPY (2016)
Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease New Insights From Epidemiology, Genetics, and Biology
Borge G. Nordestgaard
CIRCULATION RESEARCH (2016)
Surprises From Genetic Analyses of Lipid Risk Factors for Atherosclerosis
Kiran Musunuru et al.
CIRCULATION RESEARCH (2016)
Increased Remnant Cholesterol Explains Part of Residual Risk of All-Cause Mortality in 5414 Patients with Ischemic Heart Disease
Anne-Marie K. Jepsen et al.
CLINICAL CHEMISTRY (2016)
Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217
Marianne Benn et al.
EUROPEAN HEART JOURNAL (2016)
Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2016)
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Massimo F. Piepoli et al.
EUROPEAN HEART JOURNAL (2016)
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis
Michael G. Silverman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology
Borge G. Nordestgaard et al.
JOURNAL OF LIPID RESEARCH (2016)
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
Nicholas J. Viney et al.
LANCET (2016)
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease
Amit V. Khera et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Remnant Lipoprotein Cholesterol and Incident Coronary Heart Disease: The Jackson Heart and Framingham Offspring Cohort Studies
Parag H. Joshi et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)
Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial
Samia Mora et al.
CIRCULATION (2015)
Identifying an Optimal Cutpoint for the Diagnosis of Hypertriglyceridemia in the Nonfasting State
Khendi T. White et al.
CLINICAL CHEMISTRY (2015)
The high-density lipoprotein-adjusted SCORE model worsens SCORE-based risk classification in a contemporary population of 30 824 Europeans: the Copenhagen General Population Study
Martin B. Mortensen et al.
EUROPEAN HEART JOURNAL (2015)
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment
Albert Wiegman et al.
EUROPEAN HEART JOURNAL (2015)
Residual dyslipidemia according to low-density Lipoprotein cholesterol, non high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010
Nathan D. Wong et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2015)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group
Michel R. Langlois et al.
ATHEROSCLEROSIS (2014)
Residual macrovascular risk in 2013: what have we learned?
Jean-Charles Fruchart et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Discordance of Low-Density Lipoprotein (LDL) Cholesterol With Alternative LDL-Related Measures and Future Coronary Events
Samia Mora et al.
CIRCULATION (2014)
Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)
Amit V. Khera et al.
CIRCULATION (2014)
Marked effects of extreme levels of lipoprotein(a) on estimation of low-density lipoprotein cholesterol
Ramesh Saeedi et al.
CLINICAL BIOCHEMISTRY (2014)
Low Nonfasting Triglycerides and Reduced All-Cause Mortality: A Mendelian Randomization Study
Mette Thomsen et al.
CLINICAL CHEMISTRY (2014)
Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia The LAPLACE-2 Randomized Clinical Trial
Jennifer G. Robinson et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a) Prospective 15-Year Outcomes in the Bruneck Study
Peter Willeit et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
Neil J. Stone et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)
Triglycerides and cardiovascular disease
Borge G. Nordestgaard et al.
LANCET (2014)
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Anders Berg Jorgensen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Effects of Extended-Release Niacin with Laropiprant in High-Risk Patients
Martin J. Landray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
Jacy Crosby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Understanding high-density lipoprotein function in disease: Recent advances in proteomics unravel the complexity of its composition and biology
Ruth Birner-Gruenberger et al.
PROGRESS IN LIPID RESEARCH (2014)
Relations of Change in Plasma Levels of LDL-C, Non-HDL-C and apoB With Risk Reduction From Statin Therapy: A Meta-Analysis of Randomized Trials
George Thanassoulis et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2014)
The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management
Robert A. Hegele et al.
LANCET DIABETES & ENDOCRINOLOGY (2014)
Substituting non-HDL cholesterol with LDL as a guide for lipid-lowering therapy increases the number of patients with indication for therapy
Luis Masana et al.
ATHEROSCLEROSIS (2013)
Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients A Meta-Analysis
S. Matthijs Boekholdt et al.
CIRCULATION (2013)
Elevated Remnant Cholesterol Causes Both Low-Grade Inflammation and Ischemic Heart Disease, Whereas Elevated Low-Density Lipoprotein Cholesterol Causes Ischemic Heart Disease Without Inflammation
Anette Varbo et al.
CIRCULATION (2013)
Association of Apolipoprotein B and Nuclear Magnetic Resonance Spectroscopy-Derived LDL Particle Number with Outcomes in 25 Clinical Studies: Assessment by the AACC Lipoprotein and Vascular Diseases Division Working Group on Best Practices
Thomas G. Cole et al.
CLINICAL CHEMISTRY (2013)
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2013)
Lipoprotein(a): resurrected by genetics
F. Kronenberg et al.
JOURNAL OF INTERNAL MEDICINE (2013)
Friedewald-Estimated Versus Directly Measured Low-Density Lipoprotein Cholesterol and Treatment Implications
Seth S. Martin et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Extreme Lipoprotein(a) Levels and Improved Cardiovascular Risk Prediction
Pia R. Kamstrup et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Anette Varbo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Non-High-Density Lipoprotein Cholesterol, Guideline Targets, and Population Percentiles for Secondary Prevention in 1.3 Million Adults
Mohamed B. Elshazly et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2013)
Meta-Analysis of Comparison of Effectiveness of Lowering Apolipoprotein B Versus Low-Density Lipoprotein Cholesterol and Nonhigh-Density Lipoprotein Cholesterol for Cardiovascular Risk Reduction in Randomized Trials
Jennifer G. Robinson et al.
AMERICAN JOURNAL OF CARDIOLOGY (2012)
Association of LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins A Meta-analysis
S. Matthijs Boekholdt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2012)
LCAT, HDL Cholesterol and Ischemic Cardiovascular Disease: A Mendelian Randomization Study of HDL Cholesterol in 54,500 Individuals
Christiane L. Haase et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)
On-Treatment Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment With Potent Statin Therapy JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin)
Samia Mora et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
Benjamin F. Voight et al.
LANCET (2012)
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Triglycerides and Cardiovascular Disease A Scientific Statement From the American Heart Association
Michael Miller et al.
CIRCULATION (2011)
A Meta-Analysis of Low-Density Lipoprotein Cholesterol, Non-High-Density Lipoprotein Cholesterol, and Apolipoprotein B as Markers of Cardiovascular Risk
Allan D. Sniderman et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2011)
Non-HDL Cholesterol Shows Improved Accuracy for Cardiovascular Risk Score Classification Compared to Direct or Calculated LDL Cholesterol in a Dyslipidemic Population
Hendrick E. van Deventer et al.
CLINICAL CHEMISTRY (2011)
HDL Measures, Particle Heterogeneity, Proposed Nomenclature, and Relation to Atherosclerotic Cardiovascular Events
Robert S. Rosenson et al.
CLINICAL CHEMISTRY (2011)
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
M. John Chapman et al.
EUROPEAN HEART JOURNAL (2011)
Clinical implications of discordance between low-density lipoprotein cholesterol and particle number
James D. Otvos et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2011)
Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis
Amit V. Khera et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy
William E. Boden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Cardiovascular Risk-Estimation Systems in Primary Prevention Do They Differ? Do They Make a Difference? Can We See the Future?
Marie Therese Cooney et al.
CIRCULATION (2010)
Seven Direct Methods for Measuring HDL and LDL Cholesterol Compared with Ultracentrifugation Reference Measurement Procedures
W. Greg Miller et al.
CLINICAL CHEMISTRY (2010)
Lipoprotein(a) as a cardiovascular risk factor: current status
Borge G. Nordestgaard et al.
EUROPEAN HEART JOURNAL (2010)
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
LANCET (2010)
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
C. Baigent et al.
LANCET (2010)
Diagnosis and treatment of apolipoprotein B dyslipoproteinemias
Allan Sniderman et al.
NATURE REVIEWS ENDOCRINOLOGY (2010)
HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk
M. T. Cooney et al.
ATHEROSCLEROSIS (2009)
Advanced Lipoprotein Testing and Subfractionation Are Not (Yet) Ready for Routine Clinical Use
Samia Mora
CIRCULATION (2009)
Lipoprotein Particle Profiles by Nuclear Magnetic Resonance Compared With Standard Lipids and Apolipoproteins in Predicting Incident Cardiovascular Disease in Women
Samia Mora et al.
CIRCULATION (2009)
Apolipoprotein B and Cardiovascular Disease Risk: Position Statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices
John H. Contois et al.
CLINICAL CHEMISTRY (2009)
ApoB versus non-HDL-C: What to do when they disagree
Allan Sniderman et al.
CURRENT ATHEROSCLEROSIS REPORTS (2009)
Major Lipids, Apolipoproteins, and Risk of Vascular Disease
The Emerging Risk Factors Collaboration*
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Beyond Low-Density Lipoprotein Cholesterol
Benoit J. Arsenault et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Meta-Analysis of the Relationship Between Non-High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk
Jennifer G. Robinson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis
Matthias Briel et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events
Samia Mora et al.
CIRCULATION (2008)
Fasting and Nonfasting Lipid Levels Influence of Normal Food Intake on Lipids, Lipoproteins, Apolipoproteins, and Cardiovascular Risk Prediction
Anne Langsted et al.
CIRCULATION (2008)
Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease
Ruth Frikke-Schmidt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice
Allan D. Sniderman
JOURNAL OF CLINICAL LIPIDOLOGY (2008)
LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study-Implications for LDL management
William C. Cromwell et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2007)
Beyond low-density lipoprotein cholesterol: Defining the role of low-density lipoprotein heterogeneity in coronary artery disease
James O. Mudd et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Improving prediction of ischemic cardiovascular disease in the general population using apolipoprotein B -: The Copenhagen city heart study
Marianne Benn et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2007)
Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women - The EPIC-Norfolk Prospective Population study
Karim El Harchaoui et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Triglycerides and the risk of coronary heart disease - 10 158 incident cases among 262 525 participants in 29 Western prospective studies
Nadeem Sarwar et al.
CIRCULATION (2007)
Historical milestones in measurement of HDL-cholesterol: Impact on clinical and laboratory practice
Michel R. Langlois et al.
CLINICA CHIMICA ACTA (2006)
Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the veterans affairs high-density lipoprotein intervention trial
JD Otvos et al.
CIRCULATION (2006)
Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men
T Pischon et al.
CIRCULATION (2005)
Lipoprotein(a)- and low-density lipoprotein-derived cholesterol in nephrotic syndrome:: Impact on lipid-lowering therapy?
F Kronenberg et al.
KIDNEY INTERNATIONAL (2004)
Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined Hyperlipidemia
AF Ayyobi et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2003)
Share Paper
